Closed-Door Dialogue Sessions with the Health Sciences Authority (HSA)

Bridging the Gap: Regulatory Initiatives, Implementations and HSA Collaborations

The SMF’s Life Sciences Industry Group (LSIG), together with the Singapore Association of Pharmaceutical Industries (SAPI) and the SMF’s Medical Technology Industry Group (MTIG), together with the Asia Pacific Medical Technology Association (APACMed), had a fruitful annual dialogue session organised by the Health Science Authority (HSA) with the CEO of the Health Sciences Authority (HSA), Dr Mimi Choong and associates on 14 February 2022 and 14 March 2022 respectively.
HSA Dialogue
During both dialogue sessions, topics such as regulatory initiatives and collaborations, upcoming implementations and HSA initiatives were discussed. The HSA encouraged the industries to adopt a “Self-Guided” approach and use Appendix 18A, which is provided on their website and mentioned that medical devices are eligible for expedition registration pathways in more ASEAN markets.

The HSA shared that they would be aligning their directions with the Nitrosamine International Technical Working Group (NITWG) for drugs that were identified through risk assessment of impurity and mentioned that it would not be mandated should there be no findings of nitrosamine in the drug.

The World Health Organization (WHO) recently awarded the HSA as the first of 28 countries to have achieved the highest maturity level (ML 4) in the WHO’s classification of regulatory authorities for medical products. Both Chairmen of LSIG and MTIG sent their heartiest congratulations to Dr Mimi Choong for the achievement which has made Singapore one of the most recognisable countries in the pharmaceutical field.

Share This

Other News